000153.SHE Anhui Fengyuan Pharmaceutical Co Ltd
- Market cap
- CNY 2.50B
- P/E
- 29.8x
- P/B
- 1.11x
- ROE
- 5.2%
- Dividend yield
- 3.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000153.SHE undervalued?
Graham number000153.SHE trades 21.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anhui Fengyuan Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Anhui Fengyuan Pharmaceutical Co Ltd yet.
Anhui Fengyuan Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anhui Fengyuan Pharmaceutical Co Ltd
Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company offers biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine preparations, processed Chinese medicinal herbs, and raw materials. It also provides antipyretics and analgesics, gynecological and pediatric drugs, nervous system drugs, cardiovascular system drugs, urinary system drugs, nutritional drugs, and antibiotics. Anhui Fengyuan Pharmac…
Full company profileAnhui Fengyuan Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anhui Fengyuan Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.03B | 2.58B | 3.01B | 3.24B | 3.32B | 3.65B | 4.00B | 4.28B | 4.28B | 3.86B | 3.23B |
| Gross Profit | 535M | 784M | 1.17B | 1.23B | 1.15B | 1.08B | 1.12B | 1.09B | 927M | 709M | 713M |
| Operating Income | -9.26M | 96.1M | 92.5M | 124M | 131M | 157M | 219M | 213M | 205M | 186M | 166M |
| EBITDA | 165M | 205M | 199M | 228M | 248M | 287M | 332M | 350M | 340M | 309M | 157M |
| Net Income | 45.8M | 65.3M | 60.9M | 80.9M | 104M | 123M | 154M | 159M | 161M | 99.4M | 114M |
| EPS | 0.10 | 0.15 | 0.14 | 0.18 | 0.24 | 0.28 | 0.35 | 0.34 | 0.35 | 0.21 | 0.25 |
| Balance Sheet | |||||||||||
| Total Assets | 2.49B | 2.77B | 3.01B | 3.56B | 3.64B | 3.82B | 4.47B | 4.39B | 4.70B | 5.06B | 4.97B |
| Total Liabilities | 1.34B | 1.55B | 1.72B | 2.23B | 2.19B | 2.26B | 2.71B | 2.47B | 2.65B | 2.93B | 2.76B |
| Shareholders' Equity | 1.15B | 1.22B | 1.29B | 1.32B | 1.41B | 1.53B | 1.73B | 1.89B | 2.02B | 2.10B | 2.19B |
| Cash & Short-term Investments | 177M | 276M | 311M | 361M | 282M | 251M | 353M | 320M | 251M | 387M | 484M |
| Total Debt | 573M | 510M | 367M | 598M | 610M | 615M | 788M | 688M | 693M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 78.2M | 52.4M | 234M | 66.2M | 293M | 238M | 440M | 255M | 126M | 119M | - |
| Capital Expenditure | 22.2M | 48.0M | 84.6M | 146M | 191M | 157M | 81.8M | 152M | 144M | 221M | 84.7M |
| Free Cash Flow | 56.0M | 4.41M | 149M | -79.4M | 102M | 80.5M | 358M | 103M | -17.8M | -101M | 106M |
| Ratios | |||||||||||
| ROE | 4.0% | 5.4% | 4.7% | 6.1% | 7.3% | 8.0% | 8.9% | 8.4% | 8.0% | 4.7% | 5.2% |
| ROA | 1.8% | 2.4% | 2.0% | 2.3% | 2.9% | 3.2% | 3.5% | 3.6% | 3.4% | 2.0% | 2.3% |
| Net Profit Margin | 2.3% | 2.5% | 2.0% | 2.5% | 3.1% | 3.4% | 3.9% | 3.7% | 3.8% | 2.6% | 3.5% |
| Debt to Equity | 0.50x | 0.42x | 0.28x | 0.45x | 0.43x | 0.40x | 0.46x | 0.36x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anhui Fengyuan Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.25%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 81.6%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 81.2M | 0.17 | 81.6% |
| 2024 | CNY 72.2M | 0.16 | 44.9% |
| 2023 | CNY 64.2M | 0.14 | 40.3% |
| 2022 | CNY 31.2M | 0.07 | 20.2% |
| 2021 | CNY 26.3M | 0.06 | 21.4% |
| 2020 | CNY 38.4M | 0.09 | 37.0% |
| 2019 | CNY 51.7M | 0.12 | 63.9% |
| 2018 | CNY 31.7M | 0.07 | 52.0% |
| 2017 | CNY 34.4M | 0.08 | 52.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 7, 2024.
Who owns Anhui Fengyuan Pharmaceutical Co Ltd
- Insiders 36.18%
- Institutions 2.89%
- Public & others 60.93%
- Shares outstanding 465M
- Free float 334M
Anhui Fengyuan Pharmaceutical Co Ltd company profile
- Company name
- Anhui Fengyuan Pharmaceutical Co Ltd
- Ticker
- 000153.SHE
- ISIN
- CNE0000014X5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Sep 7, 2000
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,278
- Fiscal year end
- December
- Address
- No.16 Dalian Road, Hefei, China, 230051
- Phone
- 86 551 6484 6100
- Website
- bbcayy.com
About Anhui Fengyuan Pharmaceutical Co Ltd
Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company offers biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine preparations, processed Chinese medicinal herbs, and raw materials. It also provides antipyretics and analgesics, gynecological and pediatric drugs, nervous system drugs, cardiovascular system drugs, urinary system drugs, nutritional drugs, and antibiotics. Anhui Fengyuan Pharmaceutical Co., Ltd. was founded in 1997 and is based in Hefei, China.
Anhui Fengyuan Pharmaceutical Co Ltd management
10- Mr. Jun LiChief Financial Officer · born 1977
- Ms. Xiaojing ChenDeputy General Manager · born 1977
- Mr. Jinchao DuanDeputy GM & Employee Representative Director · born 1983
- Mr. Jun ZhangSecretary of the Board · born 1970
- Mr. Guo Kun LiDeputy General Manager · born 1972
- Mr. Shuang Qing YinDeputy General Manager · born 1969
- Mr. Zheng WuDeputy General Manager · born 1981
- Mr. De Hao LuDeputy General Manager · born 1980
- Mr. Tianle RuGM & Director · born 1985
- Zhirui ChenHead of Accounting Department & Accounting Supervisor